Amphetamine-induced psychotic disorder represents one of the most clinically compelling paradigms at the intersection of psychopharmacology, neurobiology, and clinical psychiatry. Characterized by profound distortions in perception, reality testing, and thought organization precipitated by central nervous system stimulants, this condition serves both as a significant public health challenge and as a foundational empirical model for idiopathic schizophrenia spectrum disorders. By examining the presentation, pathophysiology, and longitudinal course of this toxic state, clinicians and neuroscientists gain indispensable insights into dopamine neurochemistry and the neurobiological architectures of psychotic illness.
Amphetamine-Induced Psychotic Disorder
1. Concise Definition
Amphetamine-induced psychotic disorder (AIPD) is a substance-induced psychiatric condition categorized in clinical diagnostic systems by the emergence of prominent hallucinations, delusions, or disorganized thought processes that develop during, or shortly following, the excessive consumption of or withdrawal from amphetamines and related central nervous system stimulants. The disturbance is distinguished by the direct physiological consequence of the xenobiotic substance rather than an independent, idiopathic psychiatric disease, though it frequently presents with a phenomenology virtually indistinguishable from acute paranoid schizophrenia.
Diagnostic frameworks such as the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) and the International Classification of Diseases (ICD-11) require that these symptoms exceed the typical perceptual or psychological disturbances expected during mild stimulant intoxication or withdrawal, cause clinically significant distress or impairment across socio-occupational domains, and persist outside of a delirium. Although symptoms frequently remit within days to weeks of verified chemical abstinence, empirical evidence demonstrates that a distinct subgroup of patients exhibits protracted or recurrent psychotic symptoms sustained long after complete systemic clearance of the drug.
2. Etymology & Linguistic Origin
The nomenclature of amphetamine-induced psychotic disorder combines chemical, psychiatric, and pathological root words. The term amphetamine is an acronym derived from its chemical structure: alpha-methylphenethylamine. First synthesized in Germany in 1887 by Romanian chemist Lazar Edeleano, the compound received its common name when American pharmacologist Gordon Alles re-synthesized and evaluated its physiological properties in the late 1920s, patenting amphetamine sulfate as a synthetic substitute for ephedrine.
The constituent psychotic stems from the Greek noun psyche (meaning “soul,” “mind,” or “breath of life”) suffixed with -osis (a Greek suffix denoting an abnormal condition, state, or disease process), introduced into modern medical taxonomy by Austrian physician Ernst von Feuchtersleben in 1845 to describe diseases affecting the mental faculties. The designation disorder originates from Old French desordre and Latin ordinare, indicating a disruption of regular arrangement or function. Together, the composite terminology denotes an objectively verified disruption of psychic functioning directly generated by synthetic phenethylamine derivatives.
3. Pronunciation & Grammatical Form
The term is pronounced phonetically in Received Pronunciation and General American as /æmˈfɛt.ə.miːn ɪnˈdjuːst saɪˈkɒt.ɪk dɪsˈɔː.dər/ (UK) and /æmˈfɛt.ə.miːn ɪnˈduːst saɪˈkɑː.t̬ɪk dɪsˈɔːr.dɚ/ (US). Grammatically, the term functions as a compound noun phrase, wherein “amphetamine-induced” operates as an attributive compound adjective modifying the head noun phrase “psychotic disorder.” In specialized medical and neuropsychopharmacological literature, the condition is commonly represented by the initialisms AIPD or simply labeled within the broader diagnostic rubric of stimulant-induced psychosis (SIP).
4. Detailed Conceptual Explanation
The conceptual boundary of amphetamine-induced psychotic disorder encompasses a broad spectrum of neuropsychiatric disturbances linked to the potentiation of monoaminergic neurotransmission. At its core, the disorder is mediated by profound pharmacodynamic alterations within ascending mesolimbic and mesocortical pathways. Amphetamines—encompassing dextroamphetamine, mixed amphetamine salts, lisdexamfetamine, and illicit formulations such as methamphetamine—function as indirect sympathomimetic agents. Rather than acting as direct receptor agonists, they diffuse across neuronal membranes or are transported directly into the presynaptic cytoplasm via the dopamine active transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT).
Inside the presynaptic terminal, amphetamine inhibits the vesicular monoamine transporter 2 (VMAT2), displacing massive quantities of monoamines from storage vesicles into the cytosol. Concurrently, it activates the intracellular trace amine-associated receptor 1 (TAAR1), promoting the phosphorylation and subsequent functional reversal of DAT. Instead of recapturing extracellular dopamine from the synaptic cleft, the transporter reverses its direction, pumping stored cytosolic dopamine into the extracellular space. This flood of unconstrained dopamine overactivates post-synaptic D2-like dopamine receptors within the ventral striatum, nucleus accumbens, and associated limbic nodes.
Phenomenologically, this dopamine surge drives classic positive psychotic symptoms. Paranoid and persecutory delusions represent the most frequent cognitive presentation; affected individuals construct elaborate persecutory frameworks, asserting that they are monitored by law enforcement, targeted by organized syndicates, or tracked through surveillance technologies. Auditory hallucinations are widespread, ranging from unintelligible murmurs to distinct, derogatory voices that mimic the third-person commentary seen in primary schizophrenia spectrum illnesses. Visual hallucinations occur with substantially greater frequency in AIPD than in idiopathic schizophrenia, typically involving shadow-like forms, threatening intruders, or moving objects in the peripheral visual field.
Tactile and somatic hallucinations constitute a hallmark feature of stimulant-induced psychosis, most notably manifesting as formication—the false perception of insects, vermin, or parasites crawling upon or burrowing beneath the cutaneous tissue. Clinically termed Ekbom syndrome or delusional parasitosis, this state often leads patients to perform compulsive skin-picking, excoriation, and self-mutilation using needles, tweezers, or fingernails, producing distinct cutaneous lesions commonly referred to in clinical practice as “meth sores.”
5. Historical Development
The historical trajectory of amphetamine psychosis begins in the early decades of the twentieth century. While synthesized in 1887, amphetamine remained largely an experimental laboratory chemical until Gordon Alles demonstrated its psychoactive and bronchodilator capacities in 1927. In the 1930s, pharmaceutical marketing established Benzedrine inhalers as non-prescription remedies for asthma and nasal congestion. Because the inhaler’s felt strips contained high doses of free-base amphetamine, recreational consumption through extraction and ingestion spread rapidly.
During World War II, military commands across both Axis and Allied nations distributed hundreds of millions of amphetamine and methamphetamine tablets (most notably Pervitin in Nazi Germany) to combat soldiers, aviators, and naval personnel to delay fatigue, enhance alertness, and sustain combat drive. This wartime utilization sparked the first widespread epidemics of stimulant-induced psychiatric morbidity. Following the war, surplus pharmaceutical stocks in Japan triggered the first documented civilian epidemic of methamphetamine dependence and related psychotic states, documented meticulously by Japanese psychiatrists who noted cases of lingering paranoid states persisting months after cessation of use.
In Western psychiatry, the condition was definitively delineated in 1958 by British psychiatrist P. H. Connell in his seminal Maudsley Monograph, Amphetamine Psychosis. Connell documented forty-two clinical cases of individuals admitted to psychiatric facilities exhibiting delusions of persecution, auditory and visual hallucinations, and marked agitation following amphetamine misuse. Critically, Connell revealed that these patients were routinely misdiagnosed with acute paranoid schizophrenia because their mental status examinations were clinically indistinguishable. Connell pioneered the use of biochemical detection techniques, showing that psychotic symptoms resolved rapidly upon clearance of amphetamine metabolites from the urine, thereby establishing the direct pharmacological etiology of the syndrome.
6. Theoretical Foundations
The primary theoretical foundation explaining amphetamine-induced psychotic disorder is the dopamine hypothesis of psychosis. Connell’s clinical observations and subsequent animal studies conducted throughout the 1960s and 1970s provided the critical pharmacological pillar for this framework. Because amphetamines reliably trigger psychotic states in healthy volunteers and worsen psychotic symptoms in individuals with schizophrenia, researchers deduced that excessive dopaminergic activity—specifically via the hyperactivation of subcortical D2 receptors—underpins the emergence of positive psychotic symptoms across diagnostic categories.
A modern refinement of this framework is the aberrant salience hypothesis, articulated by Shitij Kapur. Under normal physiological conditions, phasic mesolimbic dopamine release signals novel or motivationally critical environmental stimuli, directing attention and cognitive processing toward survival-salient events. Amphetamines drive massive, uncoordinated, and context-independent release of dopamine throughout the striatum. Consequently, ordinary, neutral, or coincidental sensory inputs become imbued with profound personal significance and emotional intensity. Delusions develop as a top-down, cognitive attempt by the patient to construct an explanatory framework for this surge of aberrant salience, while hallucinations represent the direct sensory manifestation of internally generated representations acquiring unwarranted motivational weight.
Complementary neurobiological models emphasize behavioral and neurochemical sensitization, as formulated by Terry Robinson and Kent Berridge. Repeated, intermittent exposure to amphetamines produces enduring structural and molecular adaptations in mesolimbic circuitry, manifesting as augmented dopamine release upon subsequent drug exposure or acute stress. This sensitization framework explains why individuals with a history of AIPD often experience rapid, intense relapses into psychosis upon ingesting miniscule quantities of the drug, or even under non-pharmacological psychological stress, long after achieving sobriety. Furthermore, chronic stimulant-induced neurotoxicity compromises prefrontal cortical glutamatergic signaling, blunting top-down inhibitory control over subcortical structures and increasing vulnerability to cognitive fragmentation.
7. Key Components, Types & Dimensions
Amphetamine-induced psychotic disorder is not a uniform clinical entity; it spans distinct temporal configurations, symptomatic profiles, and severities:
- Acute Intoxication Psychosis: A transient psychotic state emerging directly during peak systemic blood concentrations of the drug, characterized by sudden-onset persecutory paranoia, hypervigilance, and perceptual distortions that typically resolve within 24 to 48 hours as the xenobiotic is cleared.
- Subacute / Protracted Post-Withdrawal Psychosis: A clinical course wherein psychotic features endure for days, weeks, or up to a month following confirmed metabolic clearance. This state often requires targeted pharmacological intervention with antipsychotic agents to break the persistent psychotic process.
- Chronic Sensitized / Persistent Psychosis: A manifestation observed particularly in severe, long-term methamphetamine users, where psychotic manifestations endure past the traditional diagnostic cut-off of one month of verified abstinence, exhibiting structural and functional persistence analogous to an unmasked or permanent chronic psychotic illness.
- Sensory-Perceptual Dimensions: Encompassing tactile hallucinations (formication, perceived subcutaneous parasite infestation), visual illusions and complex hallucinations (shadow people, armed assailants), and auditory hallucinations (derogatory voices, murmurs, rhythmic auditory distortions).
- Affective and Motoric Dimensions: Marked psychomotor agitation, panic-level anxiety, stereotyped repetitive behaviors (punding), dyskinesia, profound autonomic arousal (mydriasis, tachycardia, diaphoresis, hyperthermia), and aggressive defense behaviors triggered by perceived mortal danger.
8. Examples & Illustrative Cases
The following real-world clinical illustrations demonstrate the diverse presentations of the condition across different settings:
Case Illustration 1: Acute Methamphetamine-Induced Persecutory State
A 28-year-old individual with an eight-month history of crystal methamphetamine misuse presents to an emergency department escorted by law enforcement. The patient had barricaded himself inside his apartment, armed with an improvised weapon, after calling emergency services to report that government operatives were drilling through his floorboards and aiming laser surveillance devices through the windows. Physical examination reveals marked mydriasis, diaphoresis, resting tachycardia (heart rate: 132 bpm), and severe psychomotor agitation. The mental status examination demonstrates extreme hypervigilance, auditory hallucinations of clicking surveillance gear, and severe persecutory delusions. Comprehensive toxicological analysis verifies high concentrations of methamphetamine and amphetamine, with no other xenobiotics present. Following stabilization in a low-stimulus environment, hydration, and low-dose second-generation antipsychotic administration, his persecutory framework softens over 36 hours. By hospital day four, the delusions fully remit, with the patient expressing complete retrospective insight into the substance-driven nature of his beliefs.
Case Illustration 2: Insidious Psychosis via Prescription Amphetamine Escalation
A 21-year-old university student prescribed mixed amphetamine salts (30 mg daily) for attention-deficit/hyperactivity disorder (ADHD) begins self-escalating doses to 120–150 mg daily to manage academic stress during final examinations. Over three weeks of continuous sleep deprivation, the student develops ideas of reference, believing that radio broadcasts contain encoded messages warning of an impending academic conspiracy against them. The student begins applying opaque tape over smartphone lenses and laptop webcams. Concurrently, they experience tactile sensations described as tiny electrical threads vibrating under the skin of their forearms, resulting in repetitive excoriation. Upon outpatient psychiatric evaluation initiated by concerned family members, the diagnosis of prescription amphetamine-induced psychotic disorder is made. Cessation of the stimulant, accompanied by short-term sleep restoration via benzodiazepines and a brief course of risperidone, results in complete symptom resolution within two weeks.
9. Measurement & Assessment
Assessing and diagnosing amphetamine-induced psychotic disorder requires a multimodal approach that integrates clinical interviews, psychometric evaluations, physical examinations, and definitive laboratory assays. The primary objective is to differentiate the substance-induced state from primary psychotic disorders (such as schizophrenia, schizoaffective disorder, or bipolar I disorder with psychotic features), intoxication delirium, and secondary psychosis due to general medical conditions (e.g., autoimmune encephalitis, head trauma).
Urgent toxicological screening of urine, blood, or oral fluids using enzyme multiplied immunoassay techniques (EMIT) confirmed by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) is foundational. Qualitative and quantitative analyses detect amphetamine metabolites, establishing the presence of the drug within its biological detection window (typically 24 to 72 hours in urine for standard amphetamines, extending up to five days or longer in chronic, high-volume methamphetamine users). Clinicians must account for cross-reactivity on rapid immunoassay screens produced by common compounds such as pseudoephedrine, bupropion, labetalol, and ranitidine.
Standardized diagnostic instruments, such as the Structured Clinical Interview for DSM-5 (SCID-5) and the Mini-International Neuropsychiatric Interview (MINI), assist clinicians in systematically evaluating chronological onset, establishing whether the psychotic symptoms preceded the initiation of amphetamine consumption or persisted beyond standard clearance windows. Psychometric symptom rating scales—including the Brief Psychiatric Rating Scale (BPRS), the Positive and Negative Syndrome Scale (PANSS), and the Stimulant Psychosis Rating Scale (SPRS)—are employed to quantify the severity of positive, negative, and general psychiatric symptoms during acute and longitudinal observation.
10. Applications & Practical Significance
The clinical, legal, and operational significance of amphetamine-induced psychotic disorder spans multiple professional domains. In emergency medicine and acute psychiatry, distinguishing AIPD from an acute exacerbation of idiopathic schizophrenia is vital for clinical trajectory, prognosis, and bed management. While acute stabilization often employs identical pharmacotherapeutic tools—primarily second-generation atypical antipsychotics (e.g., olanzapine, risperidone, ziprasidone) combined with parenteral benzodiazepines (e.g., lorazepam) to treat agitation and mitigate sympathomimetic hyperarousal—the long-term treatment algorithms diverge sharply. AIPD primarily requires substance use rehabilitation, contingency management, and cognitive-behavioral interventions rather than open-ended, life-long antipsychotic maintenance.
In forensic psychiatry and legal jurisprudence, AIPD routinely features in criminal responsibility and competency evaluations. The voluntary intoxication doctrine in most common-law jurisdictions stipulates that mental impairments induced solely by voluntary substance consumption do not satisfy criteria for legal insanity or diminished capacity. However, complex legal debates arise when an individual develops persistent, unresolving psychosis that continues months after cessation, raising difficult questions regarding whether the condition constitutes a “settled” mental disease capable of supporting an insanity defense.
In occupational and public health policy, the resurgence of illicit methamphetamine distribution, alongside rising prescription stimulant availability, demands expanded harm-reduction strategies. These initiatives include low-barrier drop-in centers, mobile crisis response teams trained to de-escalate stimulant-induced paranoia without punitive violence, and integrated addiction treatment centers offering combined medical and psychosocial care.
11. Research & Empirical Evidence
Decades of empirical investigation have enriched the understanding of the neurobiological mechanics and epidemiological trajectories of AIPD. Connell’s 1958 findings were systematically reinforced by the experimental challenge studies of David S. Bell in 1973. Bell administered intravenous amphetamines to dependent individuals in controlled hospital settings, consistently demonstrating that psychotic symptoms identical to acute paranoid states could be induced in a dose-dependent fashion, frequently emerging within minutes of administration and resolving as plasma drug levels declined.
Modern epidemiological studies have clarified the long-term prognosis of individuals presenting with stimulant-induced psychosis. In a landmark nationwide longitudinal cohort study, Bramness and colleagues (2012) evaluated the rate of diagnostic transition from substance-induced psychosis to schizophrenia spectrum disorders. Analyzing data across hundreds of thousands of patient-years, the researchers discovered that approximately 25% to 30% of patients initially diagnosed with amphetamine-induced psychosis subsequently received a formal diagnosis of schizophrenia spectrum illness over a multi-year follow-up window. This transition rate was among the highest observed across all drug classes, second only to cannabis-induced psychotic disorders.
Functional neuroimaging studies utilizing Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) have illuminated the neurochemical landscape of AIPD. Research led by Volkow and colleagues revealed that chronic methamphetamine and amphetamine users display marked reductions in striatal dopamine transporter (DAT) availability, signaling significant loss or down-regulation of presynaptic terminals. Intriguingly, challenge paradigms in sensitized users demonstrate an exaggerated displacement of radioligands like [11C]raclopride, confirming an amplified, dysregulated surge of striatal dopamine release reminiscent of that seen in acute first-episode schizophrenia.
12. Cultural & Cross-Cultural Considerations
The incidence, clinical presentation, and societal response to amphetamine-induced psychotic disorder vary significantly across international jurisdictions, shaped by regional drug markets, sociocultural belief frameworks, and healthcare infrastructure. In North America and Oceania (particularly Australia and New Zealand), the rampant availability of high-purity crystalline methamphetamine (“crystal meth,” “ice”) has produced high rates of stimulant-induced psychiatric presentations in acute care facilities, heavily impacting urban health systems and rural communities alike.
In East and Southeast Asia, including Thailand, the Philippines, and Japan, methamphetamine derivatives—locally designated as yaba or shabu—have historically represented the primary illicit drug challenge. Research in these regions reveals how cultural environments shape the thematic content of persecutory delusions. While Western patients frequently present with persecutory frameworks focused on state surveillance or technological intrusions (e.g., microchips, drones, digital tracking), patients in Southeast Asian contexts may integrate traditional spiritual concepts, ancestral grievances, or local folk mythologies into their persecutory frameworks alongside modern themes.
Furthermore, cross-cultural variances in public health paradigms substantially alter clinical outcomes. Countries operating under heavily carceral approaches frequently funnel individuals experiencing acute stimulant psychosis into penal systems, where isolation, acute stress, and untreated withdrawal can exacerbate psychotic agitation. Conversely, jurisdictions that invest in medically oriented harm-reduction infrastructure, such as supervised crisis stabilization units, report reduced rates of mortality, trauma, and secondary psychiatric complications associated with the acute disorder.
13. Criticisms, Debates & Limitations
Despite robust diagnostic classifications, several contentious debates continue within psychiatric and neuroscience communities regarding the construct validity and diagnostic boundaries of amphetamine-induced psychotic disorder:
- The Latent Vulnerability vs. Direct Toxicity Debate: A primary controversy concerns whether amphetamines are capable of generating de novo persistent psychosis in a structurally and genetically neurotypical individual, or whether the substance merely acts as a chemical stressor unmasking an underlying, premorbid genetic vulnerability to schizophrenia spectrum disease. While historical high-dose experimental trials indicate that sufficiently large doses can induce paranoia in almost anyone, individuals who develop protracted or recurring episodes often demonstrate elevated polygenic risk scores for schizophrenia.
- The Arbitrary Temporal Cutoff: Both DSM-5-TR and ICD-11 employ a one-month temporal boundary; if psychotic symptoms persist for longer than four weeks following verified abstinence, clinical guidance mandates reclassifying the condition as an independent primary psychotic illness (e.g., schizophrenia). Clinical researchers in regions with severe methamphetamine epidemics argue that this one-month rule is an arbitrary construct that ignores the protracted neurotoxic adaptations, receptor dysregulations, and slow clearance kinetics of lipophilic stimulant compounds, which can generate true substance-driven psychoses lasting six months to a year.
- Diagnostic Masking and Polysubstance Confounding: In clinical practice, solitary amphetamine misuse is relatively uncommon. Most real-world cases feature co-ingestion of cannabis, alcohol, synthetic cannabinoids, or synthetic cathinones, alongside chronic sleep deprivation. Disentangling the specific causative role of the amphetamine molecule from the profound psychotogenic effects of severe, multi-day sleep deprivation and polysubstance synergy remains a formidable methodological and diagnostic challenge.
14. Related Terms & Distinctions
Differentiating amphetamine-induced psychotic disorder from allied clinical conditions is critical for accurate differential diagnosis and treatment formulation:
- Schizophrenia (Paranoid Type): Unlike AIPD, schizophrenia typically displays an insidious premorbid prodrome, widespread negative symptoms (affective flattening, avolition, alogia), persistent thought disorder, and an absence of recent sympathomimetic substance exposure. Autonomic hyperactivity and prominent visual/tactile hallucinations are substantially less common in schizophrenia than in acute AIPD.
- Brief Psychotic Disorder: Characterized by the sudden emergence of psychotic symptoms that resolve within one month, this condition develops in the absolute absence of physiological substance toxicity, withdrawal, or an underlying medical etiology, frequently emerging secondary to extreme, overwhelming psychosocial stressors.
- Cocaine-Induced Psychotic Disorder: Presents with an almost identical clinical picture of paranoia and formication (“cocaine bugs”), but stems from a pharmacologically distinct compound that acts purely as a monoamine reuptake inhibitor (DAT blocker) rather than an amphetamine-like transporter-reversing and VMAT2-disrupting agent. Cocaine-induced psychosis typically features a shorter symptomatic half-life due to rapid metabolism via plasma esterases.
- Substance Intoxication Delirium: Differentiated by fluctuating disturbances in basic attention, alertness, and global cognitive awareness. Patients with standard AIPD generally retain clear sensorium, orientation to person, place, and time, and intact cognitive arousal despite prominent hallucinations and persecutory delusions.
- Bipolar I Disorder with Psychotic Features: Involves grandiosity, affective elevation, flight of ideas, and decreased need for sleep. While amphetamine use can trigger true mania, primary bipolar mania occurs independently of substance use and follows an episodic course tied to primary affective cycles.
15. Summary / Key Takeaways
Amphetamine-induced psychotic disorder is a severe psychiatric condition triggered by the pharmacodynamic disruption of central monoamine pathways. By reversing dopamine active transporters and inhibiting vesicular monoamine storage, amphetamines trigger intense subcortical dopamine release, generating aberrant salience, persecutory delusions, auditory and visual hallucinations, and somatic disturbances like formication.
While acute presentations often resolve within days under low-stimulus conditions, supportive care, and short-term atypical antipsychotic treatment, up to 30% of affected individuals eventually transition to a chronic primary psychotic disorder. This reality underlines the role of amphetamine-induced psychosis as both a severe clinical emergency and a crucial empirical framework for unraveling the neurobiological mechanisms underlying human psychotic conditions.
References
- American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425787
- Bell, D. S. (1973). The experimental psychosis that is produced by amphetamine. Archives of General Psychiatry, 29(1), 35–40. https://doi.org/10.1001/archpsyc.1973.01750370025003
- Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Jacobsen, P. B., Pham, B. T., Rognli, E. B., & Rosvold, E. O. (2012). Amphetamine-induced psychosis—a separate diagnostic entity or primary psychosis triggered in the vulnerable?. BMC Psychiatry, 12, Article 221. https://doi.org/10.1186/1471-244X-12-221
- Connell, P. H. (1958). Amphetamine psychosis (Maudsley Monographs No. 5). Chapman & Hall.
- Kapur, S. (2003). Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry, 160(1), 13–23. https://doi.org/10.1176/appi.ajp.160.1.13
- Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research Reviews, 18(3), 247–291. https://doi.org/10.1016/0165-0173(93)90013-P